Literature DB >> 10676908

Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?

J Barrett1, Y Saunthararajah, J Molldrem.   

Abstract

It is often difficult to distinguish myelodysplastic syndrome (MDS) from severe aplastic anemia (SAA) because both can present with profoundly hypocellular bone marrows. The distinction matters because although both conditions are complicated by pancytopenia, the risk of progression to acute leukemia is much greater in MDS. This chapter reexamines the relationship between SAA and MDS. The clinical and morphological features and pathophysiology of AA (including moderate and severe forms of acquired AA) are compared with MDS and hypoplastic MDS, with particular reference to new observations implicating autoimmune processes in both conditions. SAA and hypoplastic MDS (HMDS) are discussed in the light of these findings and attempts to separate nonevolving bone marrow failure syndromes from marrow failure progressing to acute leukemia are reviewed. The weight of evidence supports a common pathophysiology and, more speculatively, a common etiology for at least some forms of AA and MDS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10676908     DOI: 10.1016/s0037-1963(00)90027-1

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  33 in total

1.  Myelodysplastic syndrome.

Authors:  Shinji Nakao; H Joachim Deeg; Takayuki Ishikawa; Judith Marsh; Alan List; Masao Tomonaga
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

2.  Paroxysmal nocturnal hemoglobinuria and myelodysplastic syndromes: clonal expansion of PIG-A-mutant hematopoietic cells in bone marrow failure.

Authors:  Neal S Young
Journal:  Haematologica       Date:  2009-01       Impact factor: 9.941

Review 3.  Infections in myelodysplastic syndromes.

Authors:  Andréa Toma; Pierre Fenaux; François Dreyfus; Catherine Cordonnier
Journal:  Haematologica       Date:  2012-06-24       Impact factor: 9.941

4.  I walk the line: how to tell MDS from other bone marrow failure conditions.

Authors:  Lukasz P Gondek; Amy E DeZern
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

5.  Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis.

Authors:  Prajwal Boddu; Hagop M Kantarjian; Guillermo Garcia-Manero; Farhad Ravandi; Srdan Verstovsek; Elias Jabbour; Gautam Borthakur; Marina Konopleva; Kapil N Bhalla; Naval Daver; Courtney D DiNardo; Christopher B Benton; Koichi Takahashi; Zeev Estrov; Sherry R Pierce; Michael Andreeff; Jorge E Cortes; Tapan M Kadia
Journal:  Blood Adv       Date:  2017-07-19

Review 6.  Inflammatory bone marrow microenvironment.

Authors:  Nils B Leimkühler; Rebekka K Schneider
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 7.  New agents in myelodysplastic syndromes.

Authors:  Elias Jabbour; Francis J Giles
Journal:  Curr Hematol Malig Rep       Date:  2006-03       Impact factor: 3.952

8.  Severe Aplastic Anemia Manifesting After Complete Remission of Acute Promyelocytic Leukemia: Is it a Fortuitous Association?

Authors:  Rajeshwari Satish Handigund; Prakash R Malur; Annasaheb J Dhumale; Akshay Bali; Maitrayee Roy; Suvarna Inumella
Journal:  Indian J Hematol Blood Transfus       Date:  2012-10-09       Impact factor: 0.900

Review 9.  Border between aplastic anemia and myelodysplastic syndrome.

Authors:  Hirohito Yamazaki; Shinji Nakao
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

Review 10.  Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab.

Authors:  Ankur R Parikh; Matthew J Olnes; A John Barrett
Journal:  Semin Hematol       Date:  2012-10       Impact factor: 3.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.